This review article by Konski A, examined the data of cost-effectiveness analyses of various radiotherapy modalities including 3DCRT, IMRT, hypofractionated RT, SBRT and PBT, as well as external beam RT verse other treatments such as watchful waiting, radical prostatectomy, cryotherapy and brachytherapy.

The author concluded that these analyses were a proxy to show value as the overall cost of medical care has risen. Cost effectiveness analyses of newer therapies, however, may need to morph into value evaluations as healthcare systems evaluate adopting value based payment models that use disease specific reimbursement.